window.pageData = {"stock":{"_id":3000000012738,"name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","exchange":"jj","indexFundFlag":1,"etfFundFlag":1,"feederFundFlag":1,"stockCode":"012738","tickerId":12738,"shortName":"广发创新药ETF联接C","currency":"CNY","inceptionDate":"2021-07-06T16:00:00.000Z","fundCollectionId":4000050300000,"followedNum":10,"status":"normal","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":140443473.71,"setUpShares":140443473.71,"masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","indexId":1000000931152,"index":{"areaCode":"cn","stockType":"index","exchange":"csi","stockCode":"931152","tickerId":931152,"name":"CS创新药","rebalancingFrequency":"semi-annually"},"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50300000","tickerId":50300000,"name":"广发基金管理有限公司"},"managers":[{"name":"罗国庆","stockType":"fund_manager","stockCode":"db20376800","exchange":"fm","tickerId":120717150830}],"targetFunds":[{"shortName":"广发创新药ETF","stockType":"fund","stockCode":"515120","exchange":"sh","tickerId":515120}],"hotMetrics":{"fss":{"stockId":3000000012738,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.026699999999999998,"f_ind_h_s_r":0.9732999999999999,"f_h_a":90059,"f_h_s_a":22528,"f_ind_h_s_r_c_1y":-0.01770000000000005,"f_ind_h_s_r_c_hy":-0.011600000000000055,"f_ins_h_s_r_c_1y":0.017699999999999997,"f_ins_h_s_r_c_hy":0.011599999999999997,"last_data_date":"2025-12-30T16:00:00.000Z"},"fpr":{"stockId":3000000012738,"type":"fpr","f_p_r_fys_ssc":5568,"f_p_r_fys_ssrp":0.5900844260822705,"f_p_r_m1_ssc":5710,"f_p_r_m1_ssrp":0.07094062007356805,"f_p_r_m3_ssc":5580,"f_p_r_m3_ssrp":0.7443986377487005,"f_p_r_m6_ssc":5264,"f_p_r_m6_ssrp":0.8605358160744823,"f_p_r_y1_ssc":4482,"f_p_r_y1_ssrp":0.731533139924124,"f_p_r_y2_ssc":3432,"f_p_r_y2_ssrp":0.816671524336928,"f_p_r_y3_ssc":2823,"f_p_r_y3_ssrp":0.874202693125443,"f_cagr_p_r_fs_ssc":5772,"f_cagr_p_r_fs_ssrp":0.9655172413793104},"fp":{"stockId":3000000012738,"type":"fp","f_p_r_fys":0.019627922853729496,"f_p_r_m1":0.04276488043288551,"f_p_r_m3":-0.04872611464968146,"f_p_r_m6":-0.08946806889193715,"f_p_r_y1":0.19408354987007814,"f_cagr_p_r_fs":-0.10261164176051685,"f_p_r_d1":0.0011818002757533197,"f_p_r_y2":0.2277024249897246,"f_cagr_p_r_fs_sic":17,"f_cagr_p_r_fs_sirp":1,"f_p_r_fys_sic":17,"f_p_r_fys_sirp":0.75,"f_p_r_m1_sic":17,"f_p_r_m1_sirp":0.75,"f_p_r_m3_sic":17,"f_p_r_m3_sirp":0.4375,"f_p_r_m6_sic":17,"f_p_r_m6_sirp":0.8125,"f_p_r_y1_sic":15,"f_p_r_y1_sirp":0.7857142857142857,"f_p_r_y2_sic":13,"f_p_r_y2_sirp":0.4166666666666667,"f_p_r_y3":-0.11312351543942989,"f_p_r_y3_sic":12,"f_p_r_y3_sirp":0.45454545454545453,"last_data_date":"2026-04-09T16:00:00.000Z"},"ff":{"stockId":3000000012738,"type":"ff","f_m_f":174930,"f_m_f_r":0.005,"f_c_f":34986,"f_c_f_r":0.001,"f_m_a_c_f":209916,"f_m_a_c_f_r":0.006,"f_m_c_f_d":"2024-09-25T16:00:00.000Z","f_c_fr":0.001,"f_fr_d":"2025-06-09T16:00:00.000Z","f_m_fr":0.005,"f_mac_fr":0.006},"f_nlacan":{"stockId":3000000012738,"type":"f_nlacan","f_nv_d":"2026-04-09T16:00:00.000Z","f_nv":0.5974,"f_nv_cr":0.0043712172158709706},"f_as":{"stockId":3000000012738,"type":"f_as","f_tas":959962179.3866999,"f_tas_d":"2025-12-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152},{"_id":3000000022104,"name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","status":"normal","indexFundFlag":1,"etfFundFlag":1,"feederFundFlag":1,"stockCode":"022104","tickerId":22104,"shortName":"广发创新药ETF联接F","currency":"CNY","__csrcFundId":9472,"exchange":"jj","masterFundFlag":null,"activeFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-01-04T00:32:33.054Z","inceptionDate":"2024-09-26T16:00:00.000Z","pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","fundCollectionId":4000050300000,"followedNum":0}],"bondHoldings":[{"_id":"69723b191987889646e70e85","date":"2025-12-30T16:00:00.000Z","fundId":3000000012737,"stockCode":"019785","stockName":"25国债13","holdings":200000,"marketCap":20120602,"netValueRatio":0.0151,"lastUpdated":"2026-01-22T14:58:33.167Z","declarationDate":"2026-01-21T16:00:00.000Z"}]},"list":[{"_id":"69ca7b897ecbd37c10afbdc8","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2025年A股市场在政策支持以及全球流动性边际宽松的共同作用下，整体呈现向上趋势，行情可分为四个阶段。第一阶段为2025年1月至3月中旬，DeepSeek驱动了A股“春季躁动”中的科技行情，推动算力、半导体以及软件等行业主题轮动上行。第二阶段为2025年3月中旬至5月中旬，“对等关税”政策反复博弈，主导了市场波动。第三阶段为2025年5月中旬至9月底，市场处于业绩空窗期，叠加国内政策再度发力，电网投资、高端制造、新能源、算力以及部分消费复苏方向表现突出，资金向景气度和确定性较高的行业集中，推动市场震荡上行。第四阶段为10月至12月底，市场转入震荡整理行情，主要原因在于全年政策与经济预期基本兑现，同时海外宏观与地缘风险上升，资金偏向防御。回顾2025年，创新药板块在前期大幅上涨后的调整，主要反映出资金面腾挪与市场对业绩兑现节奏的再博弈，而非行业基本逻辑发生根本变化基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","lastUpdated":"2026-03-30T13:32:57.597Z","mo":"展望2026年，从海外情况来看，2026年美国依然处于降息周期，政策重点从抗通胀转向防范经济下行与金融风险，整体货币政策偏向宽松。从国内市场来看，第一，财政政策保持积极，货币政策适度宽松。政府鼓励和引导扩大内需，带动投资与消费回暖。第二，科技成长板块依然值得关注。人工智能、新能源、先进制造等科技板块发展加速，政策倾向、企业盈利加速可能会推动科技板块的盈利和估值进一步提升。第三，红利资产有望构成市场的重要底仓配置。在利率中枢偏低且稳定的背景下，红利资产对险资、社保等中长期资金具备持续吸引力。第四，资金将会持续流入A股。保险资金、居民存款资金、外资等中长期资金持续增配A股，政策支持与市场预期推动权益资产配置比例上升，为市场提供上涨支撑。就创新药而言，创新药板块有望由研发积累期加速迈入商业化与全球化兑现阶段。随着海外License-out交易持续放量且大额化趋势明确，中国创新药资产在全球BD体系中的地位与定价权显著提升，BD收入叠加核心产品商业化放量，头部企业盈利能力已进入实质性改善通道。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1448844","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe95b","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2025年第三季度，A股市场呈现量价齐升的结构性牛市特征，科技板块与周期板块轮动推动市场大部分板块强势上涨。究其原因，其一，从国内宏观经济来看，伴随7月初中央财经委员会定调“反内卷”、市场基本面复苏以及通胀修复预期升温，科技和周期板块轮动上涨；其二，海外宏观流动性趋于宽松，鲍威尔明确提及货币政策立场调整，全球宏观流动性宽松预期升温；其三，从资金方面来看，市场赚钱效应与增量资金入市形成正循环，市场上涨行情下，A股低波动、高夏普的特征不断吸引以两融、个人为代表的资金入市，融资余额季度内突破2万亿、全A成交额突破3万亿、上交所新开户升温、发行回暖等迹象，均反映增量资金入市、居民存款搬家意愿强。在三方面因素推动下，尽管国内宏观经济数据、中报业绩仍在反映盈利端的压力，但A股市场在基本面预期与流动性驱动下持续走强。回顾2025年第三季度，创新药板块延续高景气，主要源于“全球化突破、政策生态优化、业绩兑现验证”。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","lastUpdated":"2026-03-09T13:47:57.161Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1372876","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe95a","date":"2025-06-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2025年上半年，A股市场整体震荡上行，节奏上主要分为三个阶段。第一阶段为1月至3月下旬，DeepSeek驱动A股“春季躁动”的科技行情。春节期间以DeepSeek为代表的人工智能大模型横空出世，叠加互联网巨头资本开支超预期等事件，引发人工智能、港股科技、机器人等科技相关主题轮动上涨。第二阶段为4月至5月中旬，“对等关税”政策不断反复主导了市场的波动。4月3日美国推出“对等关税”政策，引发全球风险资产动荡，A股大幅下跌，对美国出口较大的电子、轻工、家电等板块跌幅较大。第三阶段为5月中旬到6月底，5月中旬“日内瓦联合声明”推出，中美合谈取得较大进展，市场风险偏好逐渐回暖。6月初，海外AI突破带动国内整体情绪回暖，大盘重回活跃。回顾2025年上半年，创新药板块延续高景气，主要源于“全球化突破、政策生态优化、业绩兑现验证”。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2025-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.159Z","mo":"展望2025年下半年，看好A股和港股市场的表现。一方面，AH股的估值分位数明显低于美股，一旦美联储降息重新启动，AH资产的估值提升空间将大于美股。另一方面，弱美元环境下，全球资金有望到非美资产里寻找额外的收益，容易带动A股和港股资产估值提升。从创新药板块来看，创新药行情有望延续，核心矛盾转向业绩兑现和技术突破。出海需跟踪海外临床节点，布局具备国际化能力企业。新管线方面，关注获批药放量及新技术进展。长期看，行业“全球化+创新升级”趋势明确，具备First-in-class布局及出海优势的企业有望成为核心资产。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1342033","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe959","date":"2025-03-30T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2025年1季度，A股市场整体震荡上行，节奏上主要分为三个阶段。第一阶段为1月至春节之前，国内处于政策真空期，市场整体风险偏好较低，资金避险情绪浓厚。第二阶段为春节后至3月下旬，DeepSeek驱动A股“春季躁动”的科技行情。春节期间以DeepSeek为代表的人工智能大模型横空出世，叠加互联网巨头资本开支超预期等事件，A股与港股市场开始定价中国科技资产重估的叙事，导致人工智能、港股科技、机器人等行业主题轮动上涨。第三阶段为3月下旬至3月底，科技板块出现调整和分化，市场开始快速轮动。一方面，AI、机器人等对科技股的业绩拉动暂时难以在2025年1季报体现。另一方面，科技催化剂效果也开始逐渐减弱，科技股迎来回调，而深海科技、红利等主题行业开始快速轮动。回顾2025年1季度，多家创新药公司发布2024年财报，创新药板块总体业绩呈现高增长趋势。同时，国产创新药出海已初具规模，并且有望持续增长。未来，出海带来的国际化收入占比或将提升，并打开创新药企业的估值天花板。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2025-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.156Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1266048","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe958","date":"2024-12-30T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2024年A股市场整体呈现先抑后扬的走势，全年波动较大，但是市场整体表现较好，主要宽基指数均取得正收益，市场走势可分四个阶段。第一阶段2024年1月至2月初，受美联储加息、全球经济增长速度减弱以及投资者负面情绪蔓延的因素影响，市场快速向下调整。第二阶段2024年2月初至5月中下旬，春节后国内政策端开始发力，海外PMI超预期以及国内二手房超预期，市场迎来超跌反弹行情。第三阶段2024年5月中下旬到9月中下旬，受市场基本面复苏偏弱以及海外推迟降息的影响，市场震荡走弱。第四阶段2024年9月中下旬至12月底，相关部门推出政策组合拳，此后中央政治局会议定调积极以及地产政策接连出台，市场快速上涨，随后维持高位震荡走势。从2024年全年主要指数的表现来看，沪深300指数上涨14.68%，中证500指数上涨5.46%，创业板指数上涨13.23%，CS创新药下跌16.51%。回顾2024年，多款重磅药物通过谈判纳入医保，谈判以“加快创新药的临床应用”为重点，支持鼓励创新药发展，药品覆盖范围也不断扩大。同时，国内创新药公司的国际化进程加速，国际批准的资格认证数量与授权交易金额均快速增长。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2025-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.154Z","mo":"展望2025年，从海外市场来看，尽管存在美国的关税政策大面积展开的风险，然而特朗普政策组合存在一定矛盾性，这就意味着美国经济和降息节奏的不确定性较高。从国内市场来看，国内宏观经济政策会不断加大逆周期调节力度，并且“适度宽松”的货币政策支持力度可能大于2024年，随着经济基本面的改善和政策端的持续发力，市场整体有望保持温和复苏的态势。就创新药行业而言，在创新药政策的支持下，新上市的重磅产品有望快速实现国内商业化价值。同时，随着人口老龄化加剧和健康意识的提升，市场对创新药的需求持续增长。尽管创新药行业整体有利因素较多，但不同企业的表现可能会有所分化，看好一些具有较强研发能力和丰富产品管线的创新药企业。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1250788","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe957","date":"2024-09-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2024年第3季度市场整体先抑后扬，市场走势可分为两个阶段。第一阶段7月初至9月中旬，经济、金融、企业盈利等数据不及预期，叠加海外市场大幅波动扰动风险偏好，指数单边下行。第二阶段9月中旬至9月底，海外美联储降息落地，国内政策组合拳密集推出，驱动A股市场反弹。从2024年第3季度主要指数的表现来看，沪深300指数上涨16.07%，中证500指数上涨16.19%，创业板指数上涨29.21%，中证创新药指数上涨23.27%。回顾2024年第3季度，大部分国内创新药企业已经历过研发周期，核心品种正处在商业化高速放量阶段，相关创新药公司的股价表现亮眼。具体来说，首先，创新药板块2024年二季报业绩收入加速增长，其中有商业化产品的创新药公司收入增长显著，同时费用相对平缓渐增，利润同比快速收窄。其后，2024年7月5日《全链条支持创新药发展实施方案》发布，有望通过研发端、审批端、进院端、支付端、投融资，全方位、多角度支持创新药发展，解决创新药发展过程中的核心痛点问题。最后，商业化端医保支持国内大品种放量，叠加创新药出海提速，国产新药海外销售亮眼。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.151Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1174864","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe956","date":"2024-06-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2024年A股市场围绕上证指数关键点位反复震荡，市场走势可分为两个阶段。第一阶段受益于国内地产政策放松，措施覆盖降首付、降利率、存量房收储等多个方面，力度超市场预期，二手房成交短期也迎来改善，叠加外资回流因素，A股市场迎来一波反弹行情。第二阶段经济数据走弱，市场资金存量甚至减量博弈，市场向上动能不足，使得大盘再度下行。其中，沪深300指数上涨0.89%，中证500指数下跌8.96%，创业板指数下跌10.99%，中证创新药指数下跌26.34%。回顾2024年上半年，创新药板块走势相对其他板块偏弱，主要受到今年1季度业绩不及预期、美国众议院通过《生物安全法案》以及市场宏观因素的影响，但在结构上，减肥药股票受益于业绩高增长，股价表现亮眼。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2024-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.149Z","mo":"展望2024年下半年，随着资本市场改革深化和地产政策加码，叠加美联储降息预期临近，A股企业盈利有望企稳回升，支撑A股估值中枢上行。同时，市场中期主线将逐渐明晰。从医药板块来看，国内创新药企业将进入继PD-1抗体之后的新一轮创新产品周期，龙头创新药公司或将持续加大创新投入，一批拥有临床价值的优质创新药管线有望陆续商业化落地，持续改善国内创新药行业产品结构，预计这种改善在未来几年有加速趋势，国内创新药企业也将随之进入新一轮成长周期。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1145126","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe955","date":"2024-03-30T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的指数是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要持有广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2024年1季度，国内货币政策稳中趋宽，超预期的降准降息政策出台，广州、杭州等多地放宽限购，二手房成交出现明显好转。在此背景下，A股市场呈现先抑后扬走势，不同风格的主流宽基指数表现明显分化。其中，沪深300指数上涨3.10%，中证500指数下跌2.64%，创业板指数下跌3.87%，中证创新药指数下跌15.69%。回顾2024年1季度，创新药走势相对其他板块偏弱，主要源于短期业绩压力和美国制裁隐忧等。展望2024年全年，国内政策持续鼓励创新，国际化及新技术将持续为板块带来新的催化剂。同时，在政策新周期下差异化创新品种、刚需治疗性品种将具备更强的竞争优势，肿瘤及自身免疫等具有竞争优势的创新药品种市场需求较大。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2024-04-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.146Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1065191","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe954","date":"2023-12-30T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。在国内资产负债表修复承压以及海外美债利率超预期上行的压力下，2023年主要宽基指数大部分为负收益。其中，沪深300指数下跌11.38%，中证500指数下跌7.42%，创业板指数下跌19.41%，中证创新药产业指数下跌11.91%。回顾2023年，在行业政策调整、美债利率走高、行业整顿等多重压力下，创新药公司仍表现出较强的经营韧性，转型升级初具成效。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2024-01-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.144Z","mo":"展望2024年，从海外情况来看，随着美联储11月议息会议显著转鸽，12月美债利率自高位连续下行，进一步确立“海外政策底”，2024年美联储将开启降息周期，海外流动性预计转向宽松，中美利差有望自高位收敛，叠加海外降息及美债利率下行驱动，A股资产或将迎来估值修复。从国内情况来看，政策持续鼓励创新，国际化及新技术将打开整体空间。第一，由于新技术以及新需求的不断驱动，创新药板块的“热点”不断涌现，将持续为板块带来新的催化剂。第二，当前国际化方兴未艾，2024年创新药产品获批上市和海外授权值得期待。第三，在政策新周期下，差异化创新品种及刚需治疗性品种将具备更强的竞争优势。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1051918","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe953","date":"2023-09-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2023年3季度，全球宏观经济出现低位企稳的迹象，但由于美联储货币政策紧缩的原因，大类资产价格的表现出现了一定程度的分化。其中，沪深300指数下跌3.98%，中证500指数下跌5.13%，创业板指数下跌9.53%，中证创新药产业指数上涨2.73%。随着医保谈判规则细化以及新药评审各项政策陆续出台，有望进一步加速创新药新品上市，有助于创新药保持合理利润水平，也让药企能够集中资源研发疗效更好的新药。另外，越来越多具有研发实力的医药公司海外授权收入增加，创新药公司的盈利能力得到明显改善，创新药上市公司进入良性发展的正循环。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2023-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.141Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2023年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=983468","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe952","date":"2023-06-29T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。在宏观预期不确定性的扰动下，叠加国内经济修复低于预期以及美国终端利率预期不断上修的背景，2023年上半年A股主要指数整体呈先强后弱的走势。其中，沪深300指数下跌0.75%，中证500指数上涨2.29%，创业板指数下跌5.61%，中证创新药产业指数下跌12.55%。受海外加息预期提升以及国内存量资金博弈等因素影响，今年上半年创新药板块调整较多。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2023-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.138Z","mo":"展望2023年下半年，在美国通胀快速回落以及加息周期临近见顶的背景下，外资作为边际增量资金进场，有望带动市场情绪企稳和指数上涨。此外，2023年国内创新药企有多个管线处于中后期，国内创新药企业布局即将进入收获阶段。目前创新药行业整体处于低估状态，看好未来创新药行业基本面和国际化向好带来的估值回升，关注创新药板块的中长期投资机会。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=955047","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe951","date":"2023-03-30T16:00:00.000Z","stockId":3000000012737,"sao":"本基金跟踪的标的是中证创新药产业指数，该指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2023年1季度A股各类宽基指数出现分化，沪深300指数上涨4.63%，中证500指数上涨8.11%，创业板指数上涨2.25%，中证创新药产业指数下跌1.81%。受市场对外部宏观环境存在担忧以及投融资数据表现不佳等因素影响，创新药板块表现较弱。但是，创新药产业发展以及国际化是国内医药板块的长期方向，需求端受消费升级、人口老龄化、政策支持等因素催化，可以关注创新药板块的长期投资机会。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.136Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2023年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=879218","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe950","date":"2022-12-30T16:00:00.000Z","stockId":3000000012737,"sao":"中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2022年度A股市场各类风格的宽基指数普遍下跌，沪深300指数下跌21.63%，中证500指数下跌20.31%，创业板指下跌29.37%，创新药指数下跌25.74%。从行业来看，受经济增速下滑以及美国通胀加剧等多重因素影响，2022年31个申万一级行业中，仅煤炭和综合行业累计涨幅为正，其余行业均有不同程度的下跌。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.133Z","mo":"展望2023年，在货币政策有望延续温和宽松的格局背景下，叠加国内各地疫情好转，消费有望逐步恢复，国内经济修复确定性较强，我们较为看好创新药行业的投资机会。一方面，在近年医保常态化等政策持续鼓励创新药，医保谈判释放创新药温和降价信号。另一方面，国内药企积极推动国产创新药进入医保，未来将带来较大放量预期。此外，创新药企业加速出海脚步，不少国内上市公司的创新药研发在国内乃至世界均处于领先地位，未来国内龙头创新药企业有望迎来爆发。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=864758","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe94f","date":"2022-09-29T16:00:00.000Z","stockId":3000000012737,"sao":"中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2022年3季度A股整体呈现下跌走势，沪深300指数下跌15.16%，中证500指数下跌11.47%，创业板指下跌18.56%，创新药指数下跌21.08%。由于疫情反复以及美国加息预期的变化，汽车、新能源、电子、医药等板块调整较多。尽管受A股市场整体下跌以及疫情反复等因素影响，创新药板块3季度表现较差，但是预计未来几年会有较多重磅创新药在国内外获批上市，叠加创新药企业加速出海脚步，真正具备技术沉淀能力、优质创新能力和适应市场转型能力的龙头创新药企业将迎来爆发。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2022-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.131Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2022年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=805463","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe94e","date":"2022-06-29T16:00:00.000Z","stockId":3000000012737,"sao":"中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过 50 只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。 2022年上半年，沪深300指数下跌9.22%，中证500指数下跌12.30%，创业板指下跌15.41%，创新药指数下跌14.77%，A股整体呈现下跌走势。受市场情绪、美国通胀加息以及疫情反复等多重因素影响，前4个月A股大部分板块经历了较大调整，房地产、基建等稳增长板块表现相对强势。5月份至6月份，随着疫情的缓和以及疫情后周期稳增长政策发力，汽车、家电、新能源等板块迎来强势反弹。受市场担忧创新药谈判价格、竞争格局激烈等因素影响，上半年创新药跌幅较大。基金投资运作方面，本报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2022-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.128Z","mo":"展望下半年，随着市场情绪逐步回暖，考虑到经济弱复苏，货币政策依然维持宽松，叠加稳增长政策的出台，我们看好下半年权益类资产的表现。2季度创新药公司业绩预告陆续披露，创新药龙头公司业绩改善，创新药板块有望迎来业绩拐点。同时，未来几年会有较多重磅创新药在国内外获批上市，真正具备强研发能力、原始创新能力和商业化变现能力的龙头创新药企业将迎来爆发。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=780023","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe94d","date":"2022-03-30T16:00:00.000Z","stockId":3000000012737,"sao":"中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过 50 只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2022年1季度，沪深300指数下跌14.53%，中证500指数下跌14.06%，创业板指数下跌19.96%，中证创新药产业指数下跌11.15%。受1季度外资流出、美国通胀加息以及中概股退市等多重因素影响，CXO以及创新药的公司调整较大，相关创新药公司的估值已经进入合理区间。尽管短期仍然存在政策和市场情绪的不确定性，但考虑到未来几年会有较多重磅创新药在国内外获批上市，创新药的龙头企业或将会迎来业绩爆发。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2022-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.126Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2022年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=721626","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe94c","date":"2021-12-30T16:00:00.000Z","stockId":3000000012737,"sao":"2021年，沪深300指数下跌5.20%，中证500指数上涨15.58%，创业板指数上涨12.02%。2021年一季度市场先涨后跌，二季度受成长股基本面支撑以及流动性宽松等因素催化，A股市场出现反弹，三季度和四季度市场处于宽幅震荡行情，结构分化明显，中小盘成长风格的表现总体强于大盘价值风格。行业板块的分化很大程度上来源于政策的影响：地产链、互联网板块产业政策趋严使得其行业估值整体受到压制；相反，行业景气度较高的先进制造、新能源以及有色金属等板块全年整体表现较好。中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过50只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。回顾2021年，中证创新药产业指数下跌10.61%。中证创新药产业指数在上半年表现强劲，但受集中采购常态化以及政策不支持“伪创新”的影响，中证创新药产业指数在下半年下跌了19.17%。由于我国创新药开发起步相对国外较晚，历史上国产创新药主要集中在国外已经得到验证的靶点和技术赛道，导致新药上市即面临较为激烈的竞争格局。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生风险事件。","declarationDate":"2022-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.123Z","mo":"展望2022年，国内经济发展仍然面临各种各样的压力，但从关键数据与经济结构来看，我国经济韧性强、长期向好、发展空间大的特点没有发生改变。未来，随着一系列稳增长措施的出台，预计我国经济总体保持平稳健康发展。我们依然看好创新药板块的长期投资逻辑。我国的创新药市场已经从“泛泛创新”进入到当下“精选优质创新”的阶段，走捷径的产品会重新回到和仿制药类似的价格竞争局面；而自主创新的产品已开始走出国门，加入全球化竞争，探索更广阔的自主定价市场。","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=707621","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecf8d7fea5b3eb04fe94b","date":"2021-09-29T16:00:00.000Z","stockId":3000000012737,"sao":"中证创新药产业指数从沪深市场主营业务涉及创新药研发的上市公司证券中，选取不超过 50 只最具代表性上市公司证券作为指数样本，以反映沪深市场创新药产业上市公司证券的整体表现。作为ETF联接基金，本基金主要投资广发中证创新药ETF，同时秉承指数化被动投资策略，尽量降低跟踪误差。2021年3季度，上证指数下跌0.64%，深证成指下跌5.62%，沪深300指数下跌6.85%，中证500指数上涨4.34%，创业板指下跌6.69%，中证创新药产业指数下跌11.50%。A股大盘指数市场在3季度整体呈宽幅震荡走弱趋势，且结构分化较为明显，整体表现为上游周期行业领涨而消费、科技板块低迷；中小盘市值股票表现明显好于大盘蓝筹。A股市场出现结构分化主要受到了全球大宗商品价格大幅上涨的影响，推动上游相关企业股价上涨；而美联储逐步退出QE的路线图在3季度开始清晰，打压了成长股估值的提升。创新药板块在今年3季度出现了一定幅度的回调，主要是受到了国家集采政策以及药监局明确表示不支持“伪创新”的影响，市场对创新药及其产业链存在担忧。我国的创新药市场有较强的政策属性，在良好的政策环境与较强的资本推动下，近年来国内创新药崛起加速，未来几年将有更多重磅创新药产品在国内陆续获批上市。但值得注意的是，我国的创新药市场在当下已经慢慢从“泛泛创新”进入到“精选优质创新”的时代，同质化产品将逐渐失去竞争力，有技术沉淀的公司有望脱颖而出。基金投资运作方面，报告期内，本基金严格遵守合同要求，认真对待投资者日常申购、赎回及成份股调整等工作，运作过程中未发生任何风险事件。","declarationDate":"2021-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:47:57.121Z","fund":{"_id":3000000012737,"__csrcFundId":9472,"stockCode":"012737","shortName":"广发创新药ETF联接A","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":12737,"masterFundFlag":1,"lastUpdated":"2026-04-10T17:08:35.297Z","status":"normal","exchange":"jj","name":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金","fundCollectionId":4000050300000,"inceptionDate":"2021-07-06T16:00:00.000Z","currency":"CNY","followedNum":25,"masterFundShortName":"广发创新药ETF联接","setUpDate":"2021-07-06T16:00:00.000Z","setUpAssetScale":60533555.47,"setUpShares":60533555.47,"pinyin":"gfzzcxycyjyxkfszszqtzjjfqsljjj","__indexSourceEastMoney":1,"__indexSourceCsi":1,"etfFundFlag":1,"feederFundFlag":1,"indexFundFlag":1,"indexId":1000000931152,"managers":[{"stockCode":"db20376800","stockType":"fund_manager","exchange":"fm","tickerId":120717150830,"name":"罗国庆"}]},"announcement":{"linkText":"广发中证创新药产业交易型开放式指数证券投资基金发起式联接基金2021年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=650663","linkType":"PDF","source":"csrc_pdf"}}]}